🇺🇸 FDA
Pipeline program

CD-001

2025(666)

Phase 1 small_molecule active

Quick answer

CD-001 for Malignant Neoplasm is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Malignant Neoplasm
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials